IL308052A - Topoisomerase I inhibitor conjugate peptide dose transmitters - Google Patents
Topoisomerase I inhibitor conjugate peptide dose transmittersInfo
- Publication number
- IL308052A IL308052A IL308052A IL30805223A IL308052A IL 308052 A IL308052 A IL 308052A IL 308052 A IL308052 A IL 308052A IL 30805223 A IL30805223 A IL 30805223A IL 308052 A IL308052 A IL 308052A
- Authority
- IL
- Israel
- Prior art keywords
- topoisomerase
- inhibitors
- dosing regimens
- peptide conjugates
- conjugates
- Prior art date
Links
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 title 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 title 1
- 239000000863 peptide conjugate Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181640P | 2021-04-29 | 2021-04-29 | |
| PCT/US2022/071967 WO2022232808A1 (en) | 2021-04-29 | 2022-04-28 | Dosing regimens of peptide conjugates of topoisomerase i inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308052A true IL308052A (en) | 2023-12-01 |
Family
ID=81749580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308052A IL308052A (en) | 2021-04-29 | 2022-04-28 | Topoisomerase I inhibitor conjugate peptide dose transmitters |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240226308A1 (https=) |
| EP (1) | EP4329817A1 (https=) |
| JP (1) | JP2024516825A (https=) |
| KR (1) | KR20240019097A (https=) |
| CN (1) | CN117897175A (https=) |
| AU (1) | AU2022267389A1 (https=) |
| CA (1) | CA3218253A1 (https=) |
| CL (1) | CL2023003187A1 (https=) |
| IL (1) | IL308052A (https=) |
| MX (1) | MX2023012779A (https=) |
| TW (1) | TW202308696A (https=) |
| WO (1) | WO2022232808A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| US11555019B2 (en) | 2019-07-10 | 2023-01-17 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| WO2025186213A1 (en) | 2024-03-04 | 2025-09-12 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006078816A2 (en) | 2005-01-18 | 2006-07-27 | The Board Of Governors For Higher Education | Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide |
| EP4321168A3 (en) | 2010-07-13 | 2024-04-24 | Yale University, Inc. | Environmentally sensitive compositions |
| KR20200121800A (ko) | 2018-01-05 | 2020-10-26 | 싸이브렉사 1, 인크. | 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법 |
| MX2022000449A (es) * | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
-
2022
- 2022-04-28 CN CN202280044027.3A patent/CN117897175A/zh active Pending
- 2022-04-28 CA CA3218253A patent/CA3218253A1/en active Pending
- 2022-04-28 MX MX2023012779A patent/MX2023012779A/es unknown
- 2022-04-28 TW TW111116202A patent/TW202308696A/zh unknown
- 2022-04-28 AU AU2022267389A patent/AU2022267389A1/en active Pending
- 2022-04-28 EP EP22724607.1A patent/EP4329817A1/en active Pending
- 2022-04-28 IL IL308052A patent/IL308052A/en unknown
- 2022-04-28 JP JP2023566472A patent/JP2024516825A/ja active Pending
- 2022-04-28 US US18/288,650 patent/US20240226308A1/en active Pending
- 2022-04-28 WO PCT/US2022/071967 patent/WO2022232808A1/en not_active Ceased
- 2022-04-28 KR KR1020237040934A patent/KR20240019097A/ko active Pending
-
2023
- 2023-10-25 CL CL2023003187A patent/CL2023003187A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022267389A1 (en) | 2023-11-09 |
| US20240226308A1 (en) | 2024-07-11 |
| CL2023003187A1 (es) | 2024-05-03 |
| MX2023012779A (es) | 2024-01-16 |
| JP2024516825A (ja) | 2024-04-17 |
| CN117897175A (zh) | 2024-04-16 |
| WO2022232808A1 (en) | 2022-11-03 |
| EP4329817A1 (en) | 2024-03-06 |
| KR20240019097A (ko) | 2024-02-14 |
| TW202308696A (zh) | 2023-03-01 |
| CA3218253A1 (en) | 2022-11-03 |
| AU2022267389A9 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL308052A (en) | Topoisomerase I inhibitor conjugate peptide dose transmitters | |
| IL289542A (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| IL289949A (en) | Dosing regimens for oral complement factor d inhibitors | |
| MA50245A (fr) | Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2 | |
| PL3946464T3 (pl) | Związki i ich koniugaty | |
| LT4337652T (lt) | Nlrp3 inhibitoriai | |
| ZA202102509B (en) | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells | |
| GB202002705D0 (en) | Anti-infective bicyclic peptide conjugates | |
| IL308389A (en) | Dosing regimens for acubactadine | |
| PL4313967T3 (pl) | Inhibitory khk | |
| EP4358989A4 (en) | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | |
| SG11201911598WA (en) | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis | |
| IL289659A (en) | Peptide conjugates of microtubule-targeting agents as therapeutics | |
| IL315886A (en) | Dosing regimens for anti-CD19 agents and their uses | |
| HK40108936A (en) | Dosing regimens of peptide conjugates of topoisomerase i inhibitors | |
| PT4323338T (pt) | Inibidores de tead | |
| EP4267264C0 (en) | MULTI-COMPONENT PUTTER | |
| IL308095A (en) | Dosing regimens | |
| PT4337652T (pt) | Inibidores do nlrp3 | |
| HK40105571A (zh) | Parp7抑制剂的剂量方案 | |
| IL326369A (en) | Antibody–drug conjugates with two different types of topoisomerase I inhibitors | |
| HK40108270A (zh) | 依维替定的给药方案 | |
| HK40116355A (en) | Complement inhibitor dosing regimens | |
| GB202510805D0 (en) | Dosing regimens for orellanine | |
| IL313756A (en) | Inhibitors of the sestrin-MAPK complex |